Patent application EP19169833A (EP), filed 2019-04-17
Publication number: EP3725323A1
Title: ONCOLYTIC ADENOVIRAL VECTOR EXPRESSING A MEMBER OF THE B7 FAMILY OF COSTIMULATORY LIGANDS AND ADA
Abstract: The present invention relates to cancer therapies. More specifically, the present invention relates to oncolytic adenoviral vectors and cells and pharmaceutical compositions comprising said vectors. The present invention also relates to a use of said vectors in the manufacture of a medicament for treating cancer in a subject and a method of treating cancer in a subject. Furthermore, the present invention relates to methods of producing B7 family of immune-regulatory ligands and ADA in a cell and increasing anti-tumor effect and induction of specific immune response in a subject, as well as uses of the oncolytic adenoviral vector of the invention for producing transgenes in a cell and increasing anti-tumor effect and generation of specific immune response in a subject.
IPC codes: A61K  35/   761            A I
A61K  48/    00            A I
C07K  14/   705            A I
C12N  15/    86            A I
C12N   9/    78            A I
Claims: number: 1
text: An oncolytic adenoviral vector comprising an adenovirus serotype 5 (Ad5) nucleic acid backbone, a 24 bp deletion (D24) in the Rb binding constant region 2 of E1, a nucleic acid sequence encoding a member of the B7 family of costimulatory ligands and a nucleic acid sequence encoding ADA in the E3 region.
number: 2
text: The oncolytic adenoviral vector according to claim 1, wherein the member of the B7 family of costimulatory ligands and ADA are placed under E3 promoter.
number: 3
text: The oncolytic adenoviral vector according to claim 1, wherein the member of the B7 family of costimulatory ligands and ADA are placed under CMV(Cuo) promoter.
number: 4
text: The oncolytic adenoviral vector according to any one of claims 1-3, wherein the B7 family of costimulatory ligand is ICOSL and ADA is ADA1.
number: 5
text: The oncolytic adenoviral vector according to any one of claims 1-4, wherein the nucleic acid sequence encoding a member of the B7 family of costimulatory ligands and the nucleic acid sequence encoding ADA are connected with IRES.
number: 6
text: The oncolytic adenoviral vector according to any one of claims 1-4, wherein the nucleic acid sequence encoding the member of the B7 family of costimulatory ligands and the nucleic acid sequence encoding ADA are connected with P2A.
number: 7
text: The oncolytic adenoviral vector according to any one of claims 1-6 comprising a native E1 A promoter.
number: 8
text: The oncolytic adenoviral vector according to any one of claims 1-7 further comprising an Ad5/3 chimerism as a capsid modification.
number: 9
text: The oncolytic adenoviral vector according to any one of claims 1, 3-5 or 7-8 comprising a nucleotide sequence having at least 70% identity to SEQ ID NO: 1.
number: 10
text: A cell comprising the adenoviral vector according to any one of claims 1-9.
number: 11
text: A pharmaceutical composition comprising the adenoviral vector according to any one of claims 1-9.
number: 12
text: The adenoviral vector according to any one of claims 1-9 for use in the treatment of cancer or in the manufacture of a medicament for treating cancer in a subject.
number: 13
text: The adenoviral vector for use according to claim 12, wherein the cancer is selected from a group consisting of nasopharyngeal cancer, synovial cancer, hepatocellular cancer, renal cancer, cancer of connective tissues, melanoma, lung cancer, bowel cancer, colon cancer, rectal cancer, colorectal cancer, brain cancer, throat cancer, oral cancer, liver cancer, bone cancer, pancreatic cancer, choriocarcinoma, gastrinoma, pheochromocytoma, prolactinoma, T-cell leukemia/lymphoma, neuroma, von Hippel-Lindau disease, Zollinger-Ellison syndrome, adrenal cancer, anal cancer, bile duct cancer, bladder cancer, ureter cancer, brain cancer, oligodendroglioma, neuroblastoma, meningioma, spinal cord tumor, bone cancer, osteochondroma, chondrosarcoma, Ewing's sarcoma, cancer of unknown primary site, carcinoid, carcinoid of gastrointestinal tract, fibrosarcoma, breast cancer, Paget's disease, cervical cancer, colorectal cancer, rectal cancer, esophagus cancer, gall bladder cancer, head cancer, eye cancer, neck cancer, kidney cancer, Wilms' tumor, liver cancer, Kaposi's sarcoma, prostate cancer, lung cancer, testicular cancer, Hodgkin's disease, non-Hodgkin's lymphoma, oral cancer, skin cancer, mesothelioma, multiple myeloma, ovarian cancer, endocrine pancreatic cancer, glucagonoma, pancreatic cancer, parathyroid cancer, penis cancer, pituitary cancer, soft tissue sarcoma, retinoblastoma, small intestine cancer, stomach cancer, thymus cancer, thyroid cancer, trophoblastic cancer, hydatidiform mole, uterine cancer, endometrial cancer, vagina cancer, vulva cancer, acoustic neuroma, mycosis fungoides, insulinoma, carcinoid syndrome, somatostatinoma, gum cancer, heart cancer, lip cancer, meninges cancer, mouth cancer, nerve cancer, palate cancer, parotid gland cancer, peritoneum cancer, pharynx cancer, pleural cancer, salivary gland cancer, tongue cancer and tonsil cancer.
number: 14
text: The adenoviral vector for use according to claim 12 or 13, wherein the treatment of cancer in a subject is conducted through an intratumoral, intramuscular, intra-arterial, intravenous, intrapleural, intravesicular, intracavitary or peritoneal injection, or an oral administration.
number: 15
text: The adenoviral vector for use according to claim 14, wherein the injection or the administration is conducted several times during the treatment period, or wherein an oncolytic adenoviral vector having a different fiber knob of the capsid compared to the vector of the earlier treatment is used.
number: 16
text: The adenoviral vector for use according to any one of claims 12-15, wherein the treatment of cancer in a subject further comprises an administration of a checkpoint inhibitor, verapamil or another calcium channel blocker, autophagy inducing agents, temozolomide, chemotherapy or anti-CD20 therapy or other approaches for blocking of neutralizing antibodies, substances capable to downregulating regulatory T-cells in a subject, and/or cyclophosphamide to a subject.
number: 17
text: A method of producing a member of the B7 family of costimulatory ligands and ADA in a cell in vitro, wherein the method comprises:
number: 18
text: A use of the oncolytic adenoviral vector according to any one of claims 1-9 for producing a member of the B7 family of costimulatory ligands and ADA in a cell in vitro.
Office action: search_report, dated 2020-10-21
Rejection reasons: inventive_step_epc_56
Prior art cited: ref_id: EP2379586A1
ref_type: patent
severity: background
ref_id: WO2016126608A1
ref_type: patent
severity: background
ref_id: - ALLARD, B.; BEAVIS, P. A.; DARCY, P. K.; STAGG, J.: "Immunosuppressive Activities of Adenosine In Cancer", CURR OPIN PHARMACOL, vol. 29, 2016, pages 7 - 16, XP029689535, DOI: doi:10.1016/j.coph.2016.04.001
ref_type: npl
severity: background
ref_id: - FU, T.; HE, Q.; SHARMA, P.: "The Icos/lcosl Pathway is Required for Optimal Antitumor Responses Mediated by Anti-Ctla-4 Therapy", CANCER RES, vol. 71, 2011, pages 5445 - 54, XP055315732, DOI: doi:10.1158/0008-5472.CAN-11-1138
ref_type: npl
severity: background
ref_id: - HUTLOFF, A.; DITTRICH, A. M.; BEIER, K. C.; ELJASCHEWITSCH, B.; KRAFT, R.; ANAGNOSTOPOULOS, I.; KROCZEK, R. A.: "Icos is an Inducible T-Cell Co-Stimulator Structurally and Functionally Related To Cd28", NATURE, vol. 397, 1999, pages 263 - 6
ref_type: npl
severity: background
ref_id: - KHAYYAMIAN, S.; HUTLOFF, A.; BUCHNER, K.; GRAFE, M.; HENN, V.; KROCZEK, R. A.; MAGES, H. W.: "Icos-Ligand, Expressed on Human Endothelial Cells, Costimulates Th1 And Th2 Cytokine Secretion By Memory Cd4+ T Cells", PROC NATL ACAD SCI U S A, vol. 99, 2002, pages 6198 - 203, XP002414707, DOI: doi:10.1073/pnas.092576699
ref_type: npl
severity: background
ref_id: - KURYK, L.; HAAVISTO, E.; GAROFALO, M.; CAPASSO, C.; HIRVINEN, M.; PESONEN, S.; RANKI, T.; VASSILEV, L.; CERULLO, V.: "Synergistic Anti-Tumor Efficacy of Immunogenic Adenovirus Oncos-102 (Ad5/3-D24-Gm-Csf) And Standard of Care Chemotherapy in Preclinical Mesothelioma Model", INT J CANCER, vol. 139, 2016, pages 1883 - 93, XP055362219, DOI: doi:10.1002/ijc.30228
ref_type: npl
severity: background
ref_id: - KURYK, L.; MOLLER, A.-S. W.; JADERBERG, M.: "Combination of Immunogenic Oncolytic Adenovirus Oncos-102 With Anti-Pd-1 Pembrolizumab Exhibits Synergistic Antitumor Effect in Humanized A2058 Melanoma Hunog Mouse Model", ONCOIMMUNOLOGY, vol. 8, 2018, pages 1 - 11
ref_type: npl
severity: background
ref_id: - KUTRYB-ZAJAC, B.; KOSZALKA, P.; MIERZEJEWSKA, P.; BULINSKA, A.; ZABIELSKA, M. A.; BRODZIK, K.; SKRZYPKOWSKA, A.; ZELAZEK, L.; PELI: "Adenosine Deaminase Inhibition Suppresses Progression Of 4t1 Murine Breast Cancer by Adenosine Receptor-Dependent Mechanisms", J CELL MOL MED, vol. 22, 2018, pages 5939 - 5954
ref_type: npl
severity: background
ref_id: - LONDONO-R, L. M.; COWELL, J.; WANG, L.; ZHAO, Q.; HUANG, L.; THANOS, C.; LABARRE, M. J.; LI, X.; CEKIC, C.: "Abstract 1755: Pegylated Adenosine Deaminase (Ada2) Prevents Adenosine-Mediated Increase in Tumor Growth and Improves Antitumor Immune Responses", CANCER RESEARCH, vol. 78, 2018, pages 1755 - 1755
ref_type: npl
severity: background
ref_id: - MULLER-HAEGELE, S.; MULLER, L.; WHITESIDE, T. L.: "Immunoregulatory Activity of Adenosine and Its Role in Human Cancer Progression", EXPERT REV CLIN IMMUNOL, vol. 10, 2014, pages 897 - 914
ref_type: npl
severity: background
ref_id: - OHTA, A.: "A Metabolic Immune Checkpoint: Adenosine in Tumor Microenvironment", FRONT IMMUNOL, vol. 7, 2016, pages 109
ref_type: npl
severity: background
ref_id: WO2018218240A1
ref_type: patent
severity: background
ref_id: WO2019020543A1
ref_type: patent
severity: background
ref_id: WO2015155370A1
ref_type: patent
severity: background
ref_id: - DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 2019, YANG T ET AL: "Experimental study on the co-expression of double genes AdvCD40L-IRES2-ICOSL in mouse breast cancer model", XP002794576, Database accession no. PREV201900723486
ref_type: npl
severity: background
ref_id: - HONG JIANG ET AL: "Oncolytic Adenovirus and Tumor-Targeting Immune Modulatory Therapy Improve Autologous Cancer Vaccination", CANCER RESEARCH, vol. 77, no. 14, 31 May 2017 (2017-05-31), US, pages 3894 - 3907, XP055625811, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-17-0468
ref_type: npl
severity: background
ref_id: - AMANDA ROSEWELL SHAW ET AL: "Recent advances in oncolytic adenovirus therapies for cancer", CURRENT OPINION IN VIROLOGY, vol. 21, 1 December 2016 (2016-12-01), United Kingdom, pages 9 - 15, XP055625810, ISSN: 1879-6257, DOI: 10.1016/j.coviro.2016.06.009
ref_type: npl
severity: background
ref_id: - WEN XIAO-YAN ET AL: "Tricistronic viral vectors co-expressing interleukin-12 (IL-12) and CD80 (B7-1) for the immunotherapy of cancer: Preclinical studies in myeloma", CANCER GENE THERAPY, APPLETON & LANGE, GB, vol. 8, no. 5, 1 May 2001 (2001-05-01), pages 361 - 370, XP002298032, ISSN: 0929-1903, DOI: 10.1038/SJ.CGT.7700321
ref_type: npl
severity: background
ref_id: WO2015155370
ref_type: patent
severity: obviousness
ref_id: WO2018218240
ref_type: patent
severity: obviousness
ref_id: WO2019020543
ref_type: patent
severity: obviousness
ref_id: - YANG T ET AL, "Experimental study on the co-expression of double genes AdvCD40L-IRES2-ICOSL in mouse breast cancer model", BIOSIS, BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US, (2019), Database accession no. PREV201900723486, XP002794576 [Y] 1-18 * abstract *
ref_type: npl
severity: obviousness
ref_id: - HONG JIANG ET AL, "Oncolytic Adenovirus and Tumor-Targeting Immune Modulatory Therapy Improve Autologous Cancer Vaccination", CANCER RESEARCH, US, (20170531), vol. 77, no. 14, doi:10.1158/0008-5472.CAN-17-0468, ISSN 0008-5472, pages 3894 - 3907, XP055625811 [Y] 1-18 * figure 1 *
ref_type: npl
severity: obviousness
ref_id: - AMANDA ROSEWELL SHAW ET AL, "Recent advances in oncolytic adenovirus therapies for cancer", CURRENT OPINION IN VIROLOGY, United Kingdom, (20161201), vol. 21, doi:10.1016/j.coviro.2016.06.009, ISSN 1879-6257, pages 9 - 15, XP055625810 [Y] 1-18 * table 1 *
ref_type: npl
severity: obviousness
ref_id: - WEN XIAO-YAN ET AL, "Tricistronic viral vectors co-expressing interleukin-12 (IL-12) and CD80 (B7-1) for the immunotherapy of cancer: Preclinical studies in myeloma", CANCER GENE THERAPY, APPLETON & LANGE, GB, (20010501), vol. 8, no. 5, doi:10.1038/SJ.CGT.7700321, ISSN 0929-1903, pages 361 - 370, XP002298032 [Y] 1-18 * figure 1 *
ref_type: npl
severity: obviousness
Final disposition: pending (2020-10-21)